decisionhealth Newsletters, Part B News - 2014 Issue 3 (March)
Benchmark: Practices billed newly covered chemo codes millions of times in 2012
Subscribe or sign in to view the full article.
Article Overview
This article summarizes Medicare Part B billing benchmarks for chemotherapy drugs tied to newly covered oral antiemetic combination coverage, with a focus on utilization volume and denial-rate comparisons. It is relevant to oncology practices, coding/billing staff, and reimbursement analysts who track chemotherapy claim trends and coverage changes. The article provides a high-level benchmark table and references CMS coverage context without serving as a coding reference or policy memo.
Why This Topic Matters
Understanding which chemotherapy drugs were billed most often and how denial rates varied helps practices gauge the financial impact of coverage updates and identify claim-risk areas to review internally.
Article Sections
-
Benchmark of the week
Introduces the Medicare coverage context and frames the article as a billing benchmark for chemotherapy-related claims.
-
Chemotherapy drugs for which the oral antiemetic three-drug combination is now covered
Presents utilization benchmarks for chemotherapy drugs associated with the new coverage category.
-
Denial rates for existing anti-cancer chemotherapeutic agents, 2012
Summarizes denial-rate benchmarking for previously covered anti-cancer chemotherapy claims in 2012.
What You Will Learn
- How the article frames Medicare chemotherapy billing benchmarks
- Which general billing and denial-rate measures are discussed
- How the coverage change is positioned in relation to oncology practice revenue and claims review
- What types of data tables are included in the article
Who Should Read This
- Oncology practices
- Medical coders
- Billing staff
- Revenue cycle managers
- Reimbursement analysts
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com